AC Immune SA
ACIU2.200USD
+0.080+3.77%
Market hours （ET）Quotes delayed by 15 min
220.90MMarket Cap
LossP/E TTM
More Details of AC Immune SA Company
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Company Info
Ticker SymbolACIU
Company nameAC Immune SA
IPO dateSep 23, 2016
CEOProf. Dr. Andrea Pfeifer, Ph.D.
Number of employees133
Security typeOrdinary Share
Fiscal year-endSep 23
AddressEPFL Innovation Park
CityLAUSANNE
Stock exchangeNASDAQ Global Market Consolidated
CountrySwitzerland
Postal code1015
Phone41213459121
Websitehttps://www.acimmune.com/
Ticker SymbolACIU
IPO dateSep 23, 2016
CEOProf. Dr. Andrea Pfeifer, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Werner Lanthaler, Ph.D.
Dr. Werner Lanthaler, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
140.00K
+13.65%
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
58.01K
+49.01%
Mr. Piergiorgio Donati
Mr. Piergiorgio Donati
Chief Technical Operations Officer
Chief Technical Operations Officer
45.80K
+86.78%
Mr. Howard Donovan
Mr. Howard Donovan
Chief Human Resources Officer
Chief Human Resources Officer
40.80K
+102.61%
Mr. Christopher Roberts
Mr. Christopher Roberts
Chief Financial Officer
Chief Financial Officer
38.05K
+201.94%
Prof. Carl June, M.D.
Prof. Carl June, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
25.97K
+183.81%
Dr. Anke Post, M.D., Ph.D.
Dr. Anke Post, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
9.80K
--
Dr. Monica Shaw, M.D.
Dr. Monica Shaw, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Roy E. Twyman, M.D.
Dr. Roy E. Twyman, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Dr. Monika Buetler, Ph.D.
Prof. Dr. Monika Buetler, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Werner Lanthaler, Ph.D.
Dr. Werner Lanthaler, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
140.00K
+13.65%
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
58.01K
+49.01%
Mr. Piergiorgio Donati
Mr. Piergiorgio Donati
Chief Technical Operations Officer
Chief Technical Operations Officer
45.80K
+86.78%
Mr. Howard Donovan
Mr. Howard Donovan
Chief Human Resources Officer
Chief Human Resources Officer
40.80K
+102.61%
Mr. Christopher Roberts
Mr. Christopher Roberts
Chief Financial Officer
Chief Financial Officer
38.05K
+201.94%
Prof. Carl June, M.D.
Prof. Carl June, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
25.97K
+183.81%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Jul 22
Updated: Tue, Jul 22
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BVF Partners L.P.
19.74%
DH Capital GmbH & Co. KG
16.25%
Varuma AG
11.95%
Affiris AG
6.40%
Pfeifer (Andrea M. A Ph.D.)
2.94%
Other
42.71%
Shareholders
Shareholders
Proportion
BVF Partners L.P.
19.74%
DH Capital GmbH & Co. KG
16.25%
Varuma AG
11.95%
Affiris AG
6.40%
Pfeifer (Andrea M. A Ph.D.)
2.94%
Other
42.71%
Shareholder Types
Shareholders
Proportion
Corporation
34.60%
Hedge Fund
21.05%
Individual Investor
3.40%
Investment Advisor/Hedge Fund
2.09%
Investment Advisor
1.20%
Research Firm
1.02%
Bank and Trust
0.03%
Other
36.62%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
116
63.65M
63.39%
-3.52M
2025Q1
122
64.71M
64.45%
-3.00M
2024Q4
118
65.41M
66.11%
-3.57M
2024Q3
115
69.90M
70.65%
+1.39M
2024Q2
111
70.29M
70.97%
+1.59M
2024Q1
107
70.85M
71.52%
-2.28M
2023Q4
109
71.51M
72.19%
+11.62M
2023Q3
121
61.07M
72.18%
-889.36K
2023Q2
131
61.41M
72.77%
+1.91M
2023Q1
140
59.93M
71.03%
-2.26M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BVF Partners L.P.
19.82M
19.74%
+300.00K
+1.54%
Mar 31, 2025
DH Capital GmbH & Co. KG
16.32M
16.25%
--
--
Dec 31, 2024
Varuma AG
12.00M
11.95%
--
--
Dec 31, 2024
Affiris AG
6.43M
6.4%
-150.00K
-2.28%
May 31, 2024
Pfeifer (Andrea M. A Ph.D.)
2.96M
2.94%
+534.84K
+22.09%
Dec 31, 2024
Wells Fargo Advisors
997.62K
0.99%
+1.99K
+0.20%
Mar 31, 2025
Renaissance Technologies LLC
803.47K
0.8%
+63.27K
+8.55%
Mar 31, 2025
BlackRock Financial Management, Inc.
642.79K
0.64%
-920.44K
-58.88%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
393.51K
0.39%
-31.72K
-7.46%
Mar 31, 2025
Northern Trust Global Investments Limited
377.09K
0.38%
-25.95K
-6.44%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Health Innovation Active ETF
0%
ALPS Medical Breakthroughs ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.01%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
iShares Health Innovation Active ETF
Proportion0%
ALPS Medical Breakthroughs ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
